No hearing loss after repeated courses of tobramycin in cystic fibrosis patients

Acta Oto-Laryngologica

Volumn 130, Issue 2, 2010, Pages 253-258

  Scheenstra, Renske J ^a   Heijerman, Harry G M ^b   Zuur, Charlotte L ^d   Touw, Daan J ^d   Rijntjes, Evert ^c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Department of Pulmonology   (United States)

^c Haga Teaching Hospital   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adults; Aminoglycoside; Audiometry; Cochleotoxicity; Cystic fibrosis; Drug toxicity; Hearing loss; Ototoxicity; Tobramycin

Indexed keywords

TOBRAMYCIN;

ADOLESCENT; ADULT; ARTICLE; AUDITORY THRESHOLD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HEARING LOSS; HUMAN; MALE; PRIORITY JOURNAL; PURE TONE AUDIOMETRY;

ADULT; ANTI-BACTERIAL AGENTS; AUDIOMETRY, PURE-TONE; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEARING; HUMANS; MALE; RETROSPECTIVE STUDIES; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 75649090475     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.3109/00016480903015150     Document Type: Article

References (21)

1. Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67-91.
2. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767
3. Smith DG, Waksman SA. Tuberculostatic and tuberculocidal properties of streptomycin. J Bacteriol 1947;54:253-261
4. Voldrich L. The kinetics of streptomycin, kanamycin and neomycin in the inner ear. Acta Otolaryngol 1965;60:243-248
5. Govaerts PJ, Claes J, Van De Heyning PH, Jorens PG, Marquet J, De Broe ME. Aminoglycoside-induced ototoxicity. Toxicol Lett 1990;52:227-251
6. Cone LA. A survey of prospective, controlled clinical trials of gentamicin, tobramycin, amikacin, and netilmicin. Clin Ther 1982;5:155-162
7. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984;13(Suppl A):9-22.
8. Mulheran M, Degg C, Burr S, Morgan DW, Stableforth DE. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob Agents Chemother 2001;45:2502-2509
9. Mulherin D, Fahy J, Grant W, Keogan M, Kavanagh B, FitzGerald M. Aminoglycoside induced ototoxicity in patients with cystic fibrosis. Ir J Med Sci 1991;160:173-175
10. Mulheran M, Hyman-Taylor P, Tan KH, Lewis S, Stableforth D, Knox A, et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother 2006;50:2293-2299
11. International Organization for Standardization 2000, 2nd edn. Reference number ISO 7029:2000(E). International Standard. Acoustics - Statistical distribution of hearing thresholds as a function of age, 2008.
12. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155-163
13. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother 1987;31:594-599
14. Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, et al. Risk factors of ototoxicity after cisplatin- based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys 2007;68:1320-1325
15. Gatell JM, Ferran F, Araujo V, Bonet M, Soriano E, Traserra J, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 1987;31:1383-1387
16. Park SK, Choi D, Russell P, John EO, Jung TT. Protective effect of corticosteroid against the cytotoxicity of aminoglycoside otic drops on isolated cochlear outer hair cells. Laryngoscope 2004;114:768-771 (Pubitemid 38548795)
17. Watanabe K, Hess A, Michel O, Yagi T. Nitric oxide synthase inhibitor reduces the apoptotic change in the cisplatin-treated cochlea of guinea pigs. Anticancer Drugs 2000;11:731-735
18. Haynes DS, O'Malley M, Cohen S, Watford K, Labadie RF. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2007;117:3-15.
19. Rybak LP, Husain K, Evenson L, Morris C, Whitworth C, Somani SM. Protection by 4-methylthiobenzoic acid against cisplatin-induced ototoxicity: antioxidant system. Pharmacol Toxicol 1997;81:173-179
20. Wimmer C, Mees K, Stumpf P, Welsch U, Reichel O, Suckfull M. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol 2004;25:33-40.
21. Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside- induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med 2007;9:695-704.